SCINAI IMMUNOTHERAPEUTICS LT

Scinai reports a 22.7% revenue increase for the first half of 2026 to around $949,000. The reported net profit of about $1.57 million is largely due to a non‑cash gain from a favorable acquisition (approx. $6.4 million); the underlying business showed an operating loss of roughly $4.6 million and a gross loss of about $2.37 million. As of August 16, firm customer orders stood at around $3.1 million. Management targets CDMO revenues of about $5 million for 2026 but sees risks from low liquidity (approx. $2.85 million), high cash burn and potential need for dilution. » More on de.investing.com

Scinai Immunotherapeutics released results for the quarter ended 30 June 2026: a loss of $0.04 per share. Revenue rose to $0.5 million from $0.2 million in the year-ago quarter, an increase of 147.37 percent. In the year-ago quarter the loss per share was -$17.57. » More on finanzen.net

Scinai reports revenue of USD 949,000 for H1 2026 (prior year USD 773,000), lifted by acquired operations in Yavne, with increased cost of sales and a gross loss of about USD 2.4 million. The company shows a net profit of roughly USD 1.6 million, mainly due to a one-time gain from a favourable bargain purchase of about USD 6.4 million, while operating loss stood at about USD 4.6 million. Cash and cash equivalents amounted to around USD 2.9 million as of 30 June and equity to about USD 11.7 million; firm customer orders stood at approximately USD 3.1 million as of 16 August. Scinai announces an expanded clinical manufacturing programme with a US CDMO, received advance payments of about USD 650,000 for the programme to support an IND filing and Phase III clinical development, and will hold an investor webinar on 26 August. » More on de.investing.com